HFpEF characteristics and medications
| Disease related characteristics | ||
| NYHA class II | 10 (42%) | |
| NYHA class III | 10 (42%) | |
| NYHA class IV | 4 (17%) | |
| Six-min walk distance, m | 402±42 | |
| B-type natriuretic peptide, pg/mL | 150±26 | |
| Diabetes | 10 (42%) | |
| COPD | 2 (8%) | |
| CAD | 6 (25%) | |
| Hypertension | 20 (83%) | |
| Echocardiography | Value | Reference range |
| Ejection fraction, % | 62±1 | ≥55 |
| LV IVSD, cm | 1.1±0.1 | 0.6–1.1 |
| LV PWD, cm | 1.1±0.1 | 0.6–0.9 |
| LV ID diastole, cm | 4.5±0.2 | 3.9–5.3 |
| LV ID systole, cm | 3.0±0.1 | 2.0–4.0 |
| Peak E wave, cm/s | 84±7 | – |
| Peak A wave, cm/s | 96±11 | – |
| E/A ratio | 1.1±0.2 | 0.6–1.32 |
| E′ lateral wall, cm/s | 7±1 | 13–28 |
| E/E′ ratio | 13±2 | ≤8 |
| Mitral E-wave deceleration time, ms | 246±14 | 142–258 |
| Medications | ||
| β receptor blocker | 11 (46%) | |
| ACEi or ARB | 15 (63%) | |
| Loop diuretics | 22 (92%) | |
| Aldosterone antagonist | 16 (67%) | |
| Statin | 18 (75%) | |
| Nitrates | 5 (21%) | |
| Calcium channel blockers | 3 (13%) | |
Data are mean±SEM or % of group.
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HFpEF, heart failure with preserved ejection fraction; LV ID, left ventricle internal diameter; LV IVSD, left ventricle interventricular septum diameter; LV PWD, left ventricle posterior wall diameter; NYHA, New York Heart Association.